Trial Profile
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2023
Price :
$35
*
At a glance
- Drugs Berberine ursodeoxycholate (Primary)
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors HighTide Biopharma
- 14 Nov 2023 Results of post hoc analysis assessing the characteristics and on-treatment changes in patients who achieved an MRI response presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 24 Jun 2023 Results of post hoc analysis (n=100) assessing the effects of HTD1801 on cT1 in patients with NASHand T2DM presented at the European Association for the Study of the Liver Congress 2023
- 15 Nov 2021 Results presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases